Ishita Drugs and Industries Limited

ISHITADR6

INE806D01016

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:57 02/07/2024 BST			5-day change	1st Jan Change
68.36 ^INR	+3.62%		+1.77%	-4.98%

05-30	Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-13	Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Ishita Drugs and Industries Ltd. Appoints Niharika Shah as Company Secretary and Compliance Officer

November 13, 2018 at 03:16 pm

Ishita Drugs and Industries Ltd. announced that at its boadr meeting held on November 13, 2018, appointed Ms. Niharika Shah as Company Secretary and compliance officer with effect from 13 November, 2018.

Latest news about Ishita Drugs and Industries Limited

Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-30	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	12/08/23	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/05/23	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	14/02/23	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/08/22	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	02/11/21	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the First quarter Ended June 30, 2021	13/08/21	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/06/21	CI
Ishita Drugs and Industries Limited Announces Appointment of Srushti Pandya as Company Secretary and Compliance Officer, Effective February 4, 2021	04/02/21	CI
Ishita Drugs and Industries Limited Announces Resignation of Vijay Shah from the Post of Company Secretary and Compliance Officer	04/02/21	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	04/02/21	CI
Ishita Drugs and Industries Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	09/11/20	CI
Ishita Drugs & Industries Limited Appoints Vijay Shah as Company Secretary and Compliance Officer	31/08/20	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	13/08/20	CI
Ishita Drugs & Industries Limited Accepts Resignation of Prakash Ranjan Rastogi from the Position of Independent Non-Executive Director	30/06/20	CI
Ishita Drugs & Industries Limited Announces Resignation of Niharika Shah as Company Secretary and Compliance Officer	30/06/20	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	30/06/20	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	11/02/20	CI
Ishita Drugs & Industries Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	12/11/19	CI
Ishita Drugs & Industries Limited Approves Resignation of Shyamkumar Agrawal from the Position of Independent Director	12/11/19	CI
Ishita Drugs and Industries Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2019	13/08/19	CI

Chart Ishita Drugs and Industries Limited

Duration

Period

Chart Ishita Drugs and Industries Limited

More charts

Company Profile

Ishita Drugs and Industries Limited is a manufacturer of various active pharma ingredients (APIs) (bulk actives and their salts), drug intermediates, excipients, and fine chemicals. The Company's APIs include sulpha drugs/sulfonamides, vitamins, fluoroquinolones, antibiotics, anthelmintics, iodides and citrates (salts), food additive/excipients, and others. Its drug intermediates include 4- Sulfonamido Phenyl Hydrazine Hydrochloride (Celecoxib Intermediate), 4- Chloro Phenyl Hydrazine Hydrochloride (intermediate for Indole Carboxylic Acid), L-Alanine Benzylester Tosylate, 5 Cyano Phthalide (Citalopram Intermediate), Indole 2 Carboxylic Acid, Ethyl 3-Benzoyl Acrylate, Hexa Methyl Disilazane, 5-Chloromethopabate, and others. Its fine chemicals include salicylanilide, para bromo toluene, pyridine hydrobromide, potassium phthalimide, nicotinic acid hydrazide, 3 amino pyridine, methyl iodide. The Company has three manufacturing facilities located in the state of Gujarat.

Sector

Pharmaceuticals

Calendar

11/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ISHITA DRUGS AND INDUSTRIES LIMITED	-4.98%	2.36M
ELI LILLY AND COMPANY	+56.86%	823B
NOVO NORDISK A/S	+40.75%	641B
JOHNSON & JOHNSON	-6.57%	352B
MERCK & CO., INC.	+17.32%	324B
ABBVIE INC.	+9.94%	301B
ASTRAZENECA PLC	+15.11%	241B
ROCHE HOLDING AG	+1.43%	223B
NOVARTIS AG	+13.33%	218B
AMGEN INC.	+7.98%	167B